Abstract
Purpose
The ER-/PR-/HER2- or triple-negative (TNBC) subtype is more prevalent among women who are young, black, Hispanic, and of lower SES. The purpose of this study is to determine if young age and low SES are associated with TNBC within four mutually exclusive race/ethnicities.
Methods
The study identified 19,283 cases of TNBC and 89,089 of ER+/PR+/HER2- from the California Cancer Registry. Logistic regression analyses were conducted separately for whites, blacks, Hispanics, and Asian/Pacific Islanders (API) to compute the adjusted odds ratios (OR) for age and SES for the TNBC versus the ER+/PR+/HER2- subtype.
Results
White (OR=1.37;1.23-1.53) and Hispanic and women (OR=1.35;1.17-1.56) 30–39 had increased odds of the TNBC when compared with women 50–59 of the same race/ethnicity. Black women under 40 had the same odds, and black women 40–49 had lower odds of the TNBC as black women 50–59. White, black, and Hispanic women 70 and older had decreased or the same odds of the TNBC as 50 to 59-year-old women. API women had a similar risk of TNBC at all ages. Lower SES was associated with increased risk of TNBC only for white and Hispanic women. The odds of TNBC were no worse for API women with lower SES than API women with higher SES. SES was not statistically significant for black women.
Conclusions
When assessing the odds of TNBC within a single race/ethnicity, young age and low SES are risk factors only for white and Hispanic women, but not for black and API women.
Similar content being viewed by others
References
American Cancer Society. California Facts and Figures 2016 (2016). Atlanta: American Cancer Society . http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-047079.pdf
Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406(6797):747–752
Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98(19):10869–10874
Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295(21):2492–2502
Campleman S, Curtis R (2004) Demographic aspects of breast cancer incidence and mortality in California. In: Morris C, Kwong SL (eds) Breast Cancer in California, 2003, vol July. California Department of Health Services, Cancer Surveillance Section, Sacramento, CA, pp 1988–1999
Parise CA, Bauer KR, Brown MM, Caggiano V (2009) Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004. Breast Journal 15(6):593–602. doi:10.1111/j.1524-4741.2009.00822.x
Li X, Yang J, Peng L, Sahin AA, Huo L, Ward KC, O’Regan R, Torres MA, Meisel JL (2017) Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer. Breast Cancer Res Treat 161(2):279–287. doi:10.1007/s10549-016-4059-6
Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer 109(9):1721–1728
Brown M, Tsodikov A, Bauer KR, Parise CA, Caggiano V (2008) The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: The California Cancer Registry, 1999-2004. Cancer 112(4):737–747
Parise CA, Caggiano V (2013) Disparities in race/ethnicity and socioeconomic status: risk of mortality of breast cancer patients in the California Cancer Registry, 2000-2010. BMC Cancer 13:449. doi:10.1186/1471-2407-13-449
Vona-Davis L, Rose DP, Hazard H, Howard-McNatt M, Adkins F, Partin J, Hobbs G (2008) Triple-negative breast cancer and obesity in a rural Appalachian population. Cancer Epidemiol Biomarkers Prev 17(12):3319–3324. doi:10.1158/1055-9965.EPI-08-0544
Fritz AG (2000) International classification of diseases for oncology : ICD-O, 3rd edn. World Health Organization, Geneva, Geneva
Cancer reporting in California: Abstracting and coding procedures for hospitals. California cancer reporting system standards, Volume I (2008). California Department of Public, Cancer Surveillance and Research Branch, Sacramento, CA
ICD10Data.com (Accessed January, 2016). http://www.icd10data.com/
Bauer KR, Brown M, Creech C, Schlag NC, Caggiano V (2007) Data quality assessment of HER2 in the Sacramento Region of the California Cancer Registry. Journal of Registry Management 34(1):4–7
American Community Survey (Accessed January, 2016). U.S Department of Commerce, United States Census Bureau https://www.census.gov/programs-surveys/acs/
Yost K, Perkins C, Cohen R, Morris C, Wright W (2001) Socioeconomic status and breast cancer incidence in California for different race/ethnic groups. Cancer Causes Control 12(8):703–711
Clarke CA, Glaser SL, Keegan TH, Stroup A (2005) Neighborhood socioeconomic status and Hodgkin’s lymphoma incidence in California. Cancer Epidemiol Biomarkers Prev 14(6):1441–1447
Parikh-Patel A, Bates JH, Campleman S (2006) Colorectal cancer stage at diagnosis by socioeconomic and urban/rural status in California, 1988-2000. Cancer 107(5 Suppl):1189–1195
Zell JA, Rhee JM, Ziogas A, Lipkin SM, Anton-Culver H (2007) Race, socioeconomic status, treatment, and survival time among pancreatic cancer cases in California. Cancer Epidemiol Biomarkers Prev 16(3):546–552
Ou SH, Zell JA, Ziogas A, Anton-Culver H (2008) Low socioeconomic status is a poor prognostic factor for survival in stage I nonsmall cell lung cancer and is independent of surgical treatment, race, and marital status. Cancer 112(9):2011–2020
Yin D, Morris C, Allen M, Cress R, Bates J, Liu L (2010) Does socioeconomic disparity in cancer incidence vary across racial/ethnic groups? Cancer Causes Control 21(10):1721–1730
Telli ML, Chang ET, Kurian AW, Keegan TH, McClure LA, Lichtensztajn D, Ford JM, Gomez SL (2011) Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry. Breast Cancer Res Treat 127(2):471–478. doi:10.1007/s10549-010-1173-8
Parise CA, Bauer KR, Caggiano V (2012) Disparities in receipt of adjuvant radiation therapy after breast-conserving surgery among the cancer-reporting regions of California. Cancer 118(9):2516–2524
IBM SPSS Statistics for Windows (2012). vol 21.0. IBM Corp, Armonk NY
Lund MJ, Trivers KF, Porter PL, Coates RJ, Leyland-Jones B, Brawley OW, Flagg EW, O’Regan RM, Gabram SG, Eley JW (2009) Race and triple negative threats to breast cancer survival: a population-based study in Atlanta. GA. Breast Cancer Res Treat 113(2):357–370. doi:10.1007/s10549-008-9926-3
Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LA, Cronin KA (2014) US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst 106(5):dju055. doi:10.1093/jnci/dju1055
Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple-negative breast cancer. N Engl J Med 363(20):1938–1948. doi:10.1056/NEJMra1001389
Amirikia KC, Mills P, Bush J, Newman LA (2011) Higher population-based incidence rates of triple-negative breast cancer among young African-American women : Implications for breast cancer screening recommendations. Cancer 117(12):2747–2753
Brewster AM, Chavez-MacGregor M, Brown P (2014) Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry. Lancet Oncol 15(13):e625–e634. doi:10.1016/S1470-2045(14)70364-X
Stead LA, Lash TL, Sobieraj JE, Chi DD, Westrup JL, Charlot M, Blanchard RA, Lee JC, King TC, Rosenberg CL (2009) Triple-negative breast cancers are increased in black women regardless of age or body mass index. Breast Cancer Res 11(2):R18. doi:10.1186/bcr2242
Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121(7):2750–2767. doi:10.1172/JCI45014
Metzger-Filho O, Tutt A, de Azambuja E, Saini KS, Viale G, Loi S, Bradbury I, Bliss JM, Azim HA Jr, Ellis P, Di Leo A, Baselga J, Sotiriou C, Piccart-Gebhart M (2012) Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol 30(15):1879–1887. doi:10.1200/JCO.2011.38.2010
Mayer IA, Abramson VG, Lehmann BD, Pietenpol JA (2014) New strategies for triple-negative breast cancer–deciphering the heterogeneity. Clin Cancer Res 20(4):782–790. doi:10.1158/1078-0432.CCR-13-0583
Abramson VG, Lehmann BD, Ballinger TJ, Pietenpol JA (2015) Subtyping of triple-negative breast cancer: implications for therapy. Cancer 121(1):8–16. doi:10.1002/cncr.28914
Lehmann BD, Pietenpol JA (2015) Clinical implications of molecular heterogeneity in triple negative breast cancer. Breast 24(Suppl 2):S36–S40. doi:10.1016/j.breast.2015.07.009
Gordon NH (1995) Association of education and income with estrogen receptor status in primary breast cancer. Am J Epidemiol 142(8):796–803
Clegg LX, Reichman ME, Miller BA, Hankey BF, Singh GK, Lin YD, Goodman MT, Lynch CF, Schwartz SM, Chen VW, Bernstein L, Gomez SL, Graff JJ, Lin CC, Johnson NJ, Edwards BK (2009) Impact of socioeconomic status on cancer incidence and stage at diagnosis: selected findings from the surveillance, epidemiology, and end results: National Longitudinal Mortality Study. Cancer Causes Control 20(4):417–435. doi:10.1007/s10552-008-9256-0
Taylor A, Cheng KK (2003) Social deprivation and breast cancer. J Public Health Med 25(3):228–233
Izquierdo JN, Schoenbach VJ (2000) The potential and limitations of data from population-based state cancer registries. Am J Public Health 90(5):695–698
Parise C, Caggiano V (2014) Disparities in the risk of the ER/PR/HER2 breast cancer subtypes among Asian Americans in California. Cancer Epidemiol 38(5):556–562. doi:10.1016/j.canep.2014.08.001
Dolle JM, Daling JR, White E, Brinton LA, Doody DR, Porter PL, Malone KE (2009) Risk factors for triple-negative breast cancer in women under the age of 45 years. Cancer Epidemiol Biomarkers Prev 18(4):1157–1166. doi:10.1158/1055-9965.EPI-08-1005
Rosenberg L, Boggs DA, Wise LA, Adams-Campbell LL, Palmer JR (2010) Oral contraceptive use and estrogen/progesterone receptor-negative breast cancer among African American women. Cancer Epidemiol Biomarkers Prev 19(8):2073–2079. doi:10.1158/1055-9965.EPI-10-0428
Hunter DJ, Colditz GA, Hankinson SE, Malspeis S, Spiegelman D, Chen W, Stampfer MJ, Willett WC (2010) Oral contraceptive use and breast cancer: a prospective study of young women. Cancer Epidemiol Biomarkers Prev 19(10):2496–2502. doi:10.1158/1055-9965.EPI-10-0747
Phipps AI, Chlebowski RT, Prentice R, McTiernan A, Wactawski-Wende J, Kuller LH, Adams-Campbell LL, Lane D, Stefanick ML, Vitolins M, Kabat GC, Rohan TE, Li CI (2011) Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. J Natl Cancer Inst 103(6):470–477
Beaber EF, Malone KE, Tang MT, Barlow WE, Porter PL, Daling JR, Li CI (2014) Oral contraceptives and breast cancer risk overall and by molecular subtype among young women. Cancer Epidemiol Biomarkers Prev 23(5):755–764. doi:10.1158/1055-9965.EPI-13-0944
Chen L, Li CI, Tang MT, Porter P, Hill DA, Wiggins CL, Cook LS (2016) Reproductive Factors and Risk of Luminal, HER2-Overexpressing, and Triple-Negative Breast Cancer Among Multiethnic Women. Cancer Epidemiol Biomarkers Prev 25(9):1297–1304. doi:10.1158/1055-9965.EPI-15-1104
Atchley DP, Albarracin CT, Lopez A, Valero V, Amos CI, Gonzalez-Angulo AM, Hortobagyi GN, Arun BK (2008) Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 26(26):4282–4288. doi:10.1200/JCO.2008.16.6231
Hartman AR, Kaldate RR, Sailer LM, Painter L, Grier CE, Endsley RR, Griffin M, Hamilton SA, Frye CA, Silberman MA, Wenstrup RJ, Sandbach JF (2012) Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer. Cancer 118(11):2787–2795. doi:10.1002/cncr.26576
Churpek JE, Walsh T, Zheng Y, Moton Z, Thornton AM, Lee MK, Casadei S, Watts A, Neistadt B, Churpek MM, Huo D, Zvosec C, Liu F, Niu Q, Marquez R, Zhang J, Fackenthal J, King MC, Olopade OI (2015) Inherited predisposition to breast cancer among African American women. Breast Cancer Res Treat 149(1):31–39. doi:10.1007/s10549-014-3195-0
Zeichner SB, Stanislaw C, Meisel JL (2016) Prevention and Screening in Hereditary Breast and Ovarian Cancer. Oncology (Williston Park) 30 (10)
Acknowledgements
We wish to thank Theresa Johnson, Sharon Babcock, and Samuel Fry at the Sutter Resource Library for their valuable assistance.
Funding
This study was funded by grant 947110-1107555 from the Sutter Medical Center Sacramento Foundation.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Neither author has any disclosures to report
Ethical approval
This article does not contain any studies with human participants or animals performed by any of the authors. This research study involved analysis of existing data from the CCR without subject identifiers or intervention. Therefore, the study was categorized as exempt from institutional review board oversight.
Rights and permissions
About this article
Cite this article
Parise, C.A., Caggiano, V. Risk factors associated with the triple-negative breast cancer subtype within four race/ethnicities. Breast Cancer Res Treat 163, 151–158 (2017). https://doi.org/10.1007/s10549-017-4159-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-017-4159-y